The Heart Drug That Worked Everywhere Except the Heart
AstraZeneca and Ionis' Wainua crushed it in nerve disease, so everyone expected it to dominate in heart failure caused by the same rogue protein. A 1,432-patient Phase 3 trial just proved that biology doesn't work that way.
Imagine training for a marathon by acing every sprint workout, every hill repeat, every tempo run. Then race day comes, and you hit the wall at mile 3. That's roughly what just happened to Wainua.
AstraZeneca and Ionis had every reason to believe their RNA-based drug would crush it in heart disease. It had already proven itself in nerve disease caused by the same rogue protein. The biology lined up. The science made sense. And then the largest trial ever run in this type of heart failure came back with a flat line: no statistically significant benefit on the primary endpoint.
The CARDIO-TTRansform trial, a massive Phase 3 study spanning 1,432 patients across 20 countries, tested whether Wainua (eplontersen) could reduce cardiovascular death and recurrent cardiovascular events in patients with transthyretin amyloid cardiomyopathy, or ATTR-CM. That's a condition where a misfolded protein called TTR builds up in the heart muscle, stiffening it like concrete slowly filling a sponge. Over 140 weeks, patients on Wainua plus standard care fared no better than those on placebo plus standard care.
The result shocked the field. And the reasons behind it might reshape how we think about treating this disease entirely.
A Drug With a Flawless Résumé
Wainua already had a win under its belt. In the NEURO-TTRansform trial for hereditary ATTR polyneuropathy (where the same TTR protein attacks nerves instead of the heart), the drug was borderline spectacular.
It slashed circulating TTR levels by 81.7%. It essentially froze nerve damage in place while placebo patients deteriorated badly, with a 24.8-point difference on a key neuropathy scale. Quality of life improved significantly. The FDA approved it for polyneuropathy in 2023.
So the logic was simple: same protein, same drug, different organ. If you shut down TTR production in the liver (where approximately 90% of circulating TTR originates), you should stop amyloid from building up whether it's headed for your nerves or your heart.
That logic turned out to be dangerously incomplete.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Why the Heart Plays by Different Rules
Here's the biological plot twist. Peripheral nerves and hearts respond to amyloid buildup in fundamentally different ways.
Nerves are relatively dynamic. Stop the flow of new toxic protein, and the damage can stabilize or even partially reverse. There's a tight, almost one-to-one relationship between how much TTR you eliminate from the blood and how much better patients feel. More knockdown equals more benefit. Clean and simple.
The heart is a different beast. By the time a patient shows up with ATTR-CM symptoms, there's already a massive amyloid deposit embedded in the heart wall. We're talking years of accumulated protein that has caused thickening, stiffness, and fibrosis. Shutting off new TTR supply is like turning off a faucet when the basement is already flooded. The water stops rising, but the damage is done, and draining is painfully slow.
No one has convincingly shown that the degree of TTR reduction in the blood predicts better cardiac outcomes the way it does for nerves. The dose-response relationship that made Wainua shine in polyneuropathy simply doesn't hold in the heart, at least not on timescales that clinical trials can capture.
Add in the fact that ATTR-CM patients tend to be older, often with competing health problems like atrial fibrillation, valve disease, and general frailty. Those comorbidities dilute any signal from a TTR-specific therapy. In neuropathy trials, endpoints directly measure nerve function. In cardiology, you're trying to move mortality and hospitalization numbers in a population where lots of things can kill you.
The Stabilizer Problem Nobody Saw Coming
Trial design may have been the real villain here. And this is where it gets interesting.
At baseline, 57% of patients in both arms were already taking a TTR stabilizer (drugs like tafamidis that keep the TTR protein from misfolding). Another 24% started one during the trial. That means the vast majority of participants were already on an effective therapy. Wainua wasn't being tested against nothing; it was being tested as an add-on to drugs that already work.
Think of it this way: if you're already wearing a really good raincoat, adding a second one doesn't keep you much drier.
The data backs this up with striking clarity. In patients already on a stabilizer, Wainua showed "no treatment effect" whatsoever. Zero. But in a prespecified subgroup of patients who took Wainua without a stabilizer, there was a roughly 29% reduction in the composite endpoint, with nominal statistical significance.
That's a tantalizing signal, but "nominal" significance means the result didn't survive the strict statistical corrections required for a formal win. It's suggestive, not conclusive. Like finding a fingerprint at the crime scene but not enough for a conviction.
Wall Street and the Analyst Verdict
Analysts were quick to dissect the wreckage. Reuters reported that the heavy stabilizer use in the trial population made it nearly impossible to isolate Wainua's independent effect. Barclays went further, suggesting AstraZeneca is unlikely to fund a new monotherapy-only trial because it would simply take too long to matter competitively.
Jefferies acknowledged the miss could dent management credibility slightly but viewed the broader impact on AstraZeneca's 2030 revenue targets as limited. Fair enough: AstraZeneca is a massive company with a diversified oncology-heavy pipeline. This stings, but it's not existential.
For Ionis, the pain is more targeted. Wainua's polyneuropathy franchise remains solid. The cardiomyopathy expansion was the upside play, and that upside just evaporated, at least for now.
Both companies plan to present the full dataset at the European Society of Cardiology (ESC) Congress in August 2026. That meeting will be critical. Secondary endpoints covering exercise capacity (6-minute walk test), quality of life (KCCQ scores), and biomarkers like NT-proBNP could tell a more nuanced story. Or they could confirm the disappointment.
Winners, Losers, and a Booming Market
Three approved therapies now compete for the growing ATTR-CM prize, and Wainua's stumble reshuffles the deck.
Pfizer's tafamidis (Vyndaqel) remains the anchor. Approved for ATTR-CM since 2019, it's the drug physicians know best. BridgeBio's acoramidis (Attruby), approved in late 2024, is positioned as the more potent stabilizer challenger, and Bayer backed that bet with a $310 million upfront and near-term milestone deal for European rights.
Then there's Alnylam's vutrisiran (Amvuttra), which gained its ATTR-CM label in March 2025 after showing a roughly 28% reduction in mortality and cardiovascular events. AMVUTTRA revenue hit $492 million in Q2 2025, and the company raised full-year TTR franchise guidance to approximately $2.5 billion.
With Wainua sidelined in cardiomyopathy, Alnylam now essentially owns the gene-silencing lane in ATTR-CM. No antisense competitor is knocking on the door. That's good for Alnylam's pricing power and bad for anyone hoping competition would bring costs down (these therapies can run north of $500,000 per year).
The Bigger Question This Raises
The Wainua miss isn't just a commercial setback. It forces the field to confront an uncomfortable question: can you extrapolate drug success across disease subtypes driven by the same protein?
For years, the assumption was that TTR silencing would work wherever TTR causes problems. The polyneuropathy data made that assumption feel like a slam dunk. CARDIO-TTRansform just reminded everyone that biology is local. What works in one tissue may not translate to another, especially when the target organ has fundamentally different repair mechanisms and the patient population has fundamentally different competing risks.
This lesson extends well beyond ATTR. Across biotech, companies routinely try to expand drugs into adjacent indications based on shared molecular targets. Sometimes it works beautifully. Sometimes you get a 1,432-patient trial that proves the limits of extrapolation.
The monotherapy subgroup signal keeps a flicker of hope alive. Gene silencing may still have a role in ATTR-CM, perhaps as a first-line treatment before stabilizers, perhaps in earlier-stage patients, perhaps with a different trial design altogether. But proving that would require a new, expensive, years-long study. And in a market where three drugs are already fighting for share, the commercial window may be closing.
For now, the heart drug that worked everywhere except the heart sits in limbo, waiting for ESC and a second chance that may never come.
5 min read
The NIH Just Got a Haircut That Could Leave Biotech Bald
The NIH faces a historic 39.3% budget cut that would slash funding to levels not seen since 2003. A Senate hearing just examined what that means for the research pipeline that feeds every corner of the biotech industry.
